The Australian Institute of Health and Welfare (AIHW) has co-ordinated provision of data to the OECD’s HCQO project since 2011. Tables 1.1-1.6 list the HCQO indicators requested for the 2021 collection, indicates whether data for Australia were available and provided and, if so, outlines the data sources and the latest data reference period for the data reported to the OECD. The tables also indicate the name used in this publication to refer to the OECD indicators.
All data tables submitted to the OECD for this collection were prepared by the AIHW, except for the Cancer care indicators which were provided to the OECD by the CONCORD program.
Table 1.1: Acute care HCQO indicators, 2021
| Acute care HCQO indicator requested |
Indicator name used in this report |
Data source |
Latest data reported to OECD (year) |
| Patient-based AMI 30 day (in-hospital and out of hospital) mortality |
Not provided |
. . |
. . |
| Admission-based AMI 30 day in-hospital mortality |
AMI in-hospital mortality rate |
AIHW NHMD |
2018–19 |
| Patient-based hemorrhagic stroke 30 day (in-hospital and out of hospital) mortality |
Not provided |
. . |
. . |
| Admission-based hemorrhagic stroke 30 day in-hospital mortality |
Haemorrhagic stroke in-hospital mortality rate |
AIHW NHMD |
2018–19 |
| Patient-based ischemic stroke 30 day (in-hospital and out of hospital) mortality |
Not provided |
. . |
. . |
| Admission-based ischemic stroke 30 day in-hospital mortality |
Ischaemic stroke in-hospital mortality rate |
AIHW NHMD |
2018–19 |
| Hip fracture surgery initiated within 2 calendar days after admission to the hospital |
Not provided |
. . |
. . |
Table 1.2: Cancer care HCQO indicators, 2021
| Cancer care HCQO indicator requested |
Indicator name used in this report |
Data source |
Latest data reported to OECD (period) |
| Breast cancer 5-year net survival rate |
Breast cancer 5-year net survival rate |
CONCORD program |
2010–14 |
| Cervical cancer 5-year net survival rate |
Cervical cancer 5-year net survival rate |
CONCORD program |
2010–14 |
| Colon cancer 5-year net survival rate |
Colon cancer 5-year net survival rate |
CONCORD program |
2010–14 |
| Rectal cancer 5-year net survival rate |
Rectal cancer 5-year net survival rate |
CONCORD program |
2010–14 |
| Childhood acute lymphoblastic leukaemia 5-year net survival rate |
Childhood acute lymphoblastic leukaemia 5-year net survival rate |
CONCORD program |
2010–14 |
| Lung cancer 5-year net survival rate |
Lung cancer 5-year net survival rate |
CONCORD program |
2010–14 |
| Stomach cancer 5-year net survival rate |
Stomach cancer 5-year net survival rate |
CONCORD program |
2010–14 |
Table 1.3: Patient experiences HCQO indicators, 2021
| Patient experiences HCQO indicator requested |
Indicator name used in this report |
Data source |
Latest data reported to OECD (period) |
| Consultation skipped due to costs |
Consultation skipped due to costs |
ABS Patient Experience Survey |
2019–20 |
| Medical tests, treatment or follow-up skipped due to costs |
Medical tests skipped due to costs |
ABS Patient Experience Survey |
2019–20 |
| Prescribed medicines skipped due to costs |
Prescribed medicines skipped due to costs |
ABS Patient Experience Survey |
2019–20 |
| Doctor spending enough time with patients during the consultation |
Patient having enough time with doctor |
ABS Patient Experience Survey |
2019–20 |
| Regular doctor spending enough time with patients during the consultation |
Not provided |
. . |
. . |
| Doctor providing easy-to-understand explanations |
Not provided |
. . |
. . |
| Regular doctor providing easy-to-understand explanations |
Not provided |
. . |
. . |
| Doctor giving opportunity to ask questions or raise concerns |
Not provided |
. . |
. . |
| Regular doctor giving opportunity to ask questions or raise concerns |
Not provided |
. . |
. . |
| Doctor involving patients in decisions about care or treatment |
Not provided |
. . |
. . |
| Regular doctor involving patients in decisions about care or treatment |
Not provided |
. . |
. . |
Table 1.4: Patient safety HCQO indicators, 2021
| Patient safety HCQO indicator requested |
Indicator name used in this report |
Data source |
Latest data reported to OECD (year) |
| Retained surgical item or unretrieved device fragment |
Retained surgical item or unretrieved device fragment |
AIHW NHMD |
2018–19 |
| Postoperative pulmonary embolism – hip and knee replacement discharges |
Post-operative pulmonary embolism – hip and knee replacement discharges |
AIHW NHMD |
2018–19 |
| Postoperative deep vein thrombosis – hip and knee replacement discharges |
Post-operative deep vein thrombosis – hip and knee replacement discharges |
AIHW NHMD |
2018–19 |
| Postoperative sepsis – abdominal discharges |
Post-operative sepsis – abdominal discharges |
AIHW NHMD |
2018–19 |
| Postoperative wound dehiscence |
Post-operative wound dehiscence |
AIHW NHMD |
2018–19 |
| Obstetric trauma vaginal delivery with instrument |
Obstetric trauma after vaginal delivery with instrument |
AIHW NHMD |
2018–19 |
| Obstetric trauma vaginal delivery without instrument |
Obstetric trauma after vaginal delivery without instrument |
AIHW NHMD |
2018–19 |
Table 1.5: Prescribing in primary care HCQO indicators, 2021
| Prescribing in primary care HCQO requested |
Indicator name used in this report |
Data source |
Latest data reported to OECD (year) |
| Adequate use of cholesterol lowering treatment in people with diabetes (DDDs/Days) |
People with diabetes with at least one prescription of cholesterol lowering medication |
PBS |
2020 |
| First choice antihypertensives for people with diabetes (DDDs/Days) |
People with diabetes with prescription of first choice antihypertensive medication |
PBS |
2020 |
| Long-term use of benzodiazepines and related drugs in ≥65 years of age (≥365 DDDs/Days per year) |
Long-term benzodiazepine use among older adults |
PBS |
2020 |
| Use of long-acting benzodiazepines in ≥65 years of age |
Long-acting benzodiazepine use among older adults |
PBS |
2020 |
| Volume of cephalosporines and quinolones as a proportion of all systemic antibiotics prescribed (DDDs) |
Volume of second line antibiotics as a share of total volume
|
PBS |
2020 |
| Overall volume of antibiotics for systemic use prescribed (DDDs) |
Total volume of antibiotics for systemic use |
PBS |
2020 |
| Any anticoagulating drug in combination with an oral NSAID |
Long-term prescription of any anticoagulating drug in combination with an oral nonsteroidal anti-inflammatory drug (NSAID) |
PBS |
2020 |
| Proportion of 75 years and over who are taking more than 5 medications concurrently |
Polypharmacy among people aged 75 and over |
PBS |
2020 |
| Overall volume of opioids prescribed |
Overall volume of opioids prescribed |
PBS |
2020 |
| Proportion of the population who are chronic opioid users |
Proportion of the population who are chronic opioid users |
PBS |
2020 |
| Proportion of people 65 and over prescribed antipsychotics |
Proportion of older adults prescribed antipsychotics |
PBS |
2020 |
Table 1.6: Primary care HCQO indicators, 2021
| Primary care HCQO requested |
Indicator name used in this report |
Data source |
Latest data reported to OECD (year) |
| Asthma hospital admission |
Asthma hospital admission rate |
AIHW NHMD |
2018–19 |
| Chronic obstructive pulmonary disease (COPD) hospital admission |
COPD hospital admission rate |
AIHW NHMD |
2018–19 |
| Congestive heart failure (CHF) hospital admission |
CHF hospital admission rate |
AIHW NHMD |
2018–19 |
| Hypertension hospital admission |
Hypertension hospital admission rate |
AIHW NHMD |
2018–19 |
| Diabetes hospital admission |
Diabetes hospital admission rate |
AIHW NHMD |
2018–19 |
| Admission-based diabetes lower extremity amputation |
Diabetes lower extremity amputation rate |
AIHW NHMD |
2018–19 |
| Patient-based diabetes lower extremity amputation |
Not provided |
AIHW NHMD |
2018–19 |
